

Publikationen (Originalarbeiten)

Publikationen in Fachzeitschriften sind wissenschaftliche Arbeiten die auf Forschung und Erfahrung basierend, Kollegen und Kolleginnen weltweit in englischer Sprache zur Verfügung stehen.

- 1 Dürig J, Nüchel H, Hüttmann A, Kruse E, Hölter T, Halfmeyer K, Führer A, Rudolph R, Kalhori N, Nusch A, Deaglio S, Malavasi F, Möröy T, Klein-Hitpass L, Dührsen U:
Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia.
Blood 2003; 101:2748-55
- 2 Nüchel H, Dürig J, Dührsen U:
Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.
Annals of Hematology 2003; 82:481-6vv
- 3 Dürig J, Nüchel H, Cremer M, Führer A, Halfmeyer K, Fandrey J, Möröy T, Klein-Hitpass L, Dührsen U:
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
Leukemia 2003; 17:2426-34
- 4 Nüchel H, Frey U, Aral N, Dürig J, Dührsen U, Siffert W:
The CC genotype of the C825T polymorphism of the G protein b3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemia.
Leukemia and Lymphoma 2003; 44:1739-1743
- 5 Nüchel H, Frey UH, Dürig J, Dührsen U, Siffert W:
1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome.
European Journal of Haematology 2004; 72:259-63
- 6 Nüchel H, Meller D, Steuhl KP, Dührsen U:
Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
European Journal of Haematology 2004; 73:258-62
- 7 Nüchel H, Frey UH, Dürig J, Dührsen U, Siffert W:
Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B-cells in vitro and disease progression in chronic lymphocytic leukemia.

Leukemia 2004; 18:1816-1823

- 8 Nüchel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H:
HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukaemia.
Blood 2005; 105:1694-8
- 9 Frey UH, Nüchel H, Dobrev D, Manthey I, Sandalcioglu IE, Eisenhardt A, Worm K, Hauner H, Siffert W:
Quantification of G protein Gas subunit splice variants in different human tissues and cells using Pyrosequencing.
Gene Expression 2004; 12:69-81
- 10 Nüchel H, Frey UH, Röth A, Dührsen U, Siffert W:
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
European Journal of Pharmacology 2005; 514:217-24
- 11 Müller-Beissenhirtz H, Kasper C, Nüchel H, Dührsen U:
Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
Annals of Hematology 2005; 84:796-801
- 12 Hüttmann A, Dührsen U, Stypmann J, Noppeney R, Nüchel H, Neumann T, Gutersohn A, Nikol S, Erbel R:
Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure Feasibility, safety and effects on exercise tolerance and cardiac function.
Basic Research of Cardiology 2006; 101:78-86
- 13 Novotny JR, Nüchel H, Dührsen U:
Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia.
European Journal of Haematology 2006, 76:299-308
- 14 Nüchel H, Novotny JR, Noppeney R, Savidou I, Dührsen U:
Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry.
Clinical and Laboratory Haematology 2006, 28:22-29
- 15 Nüchel H, Frey UH, Sellmann L, Bau M, Dürig J, Dührsen U, Siffert W:
Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival.

Leukemia 2006, 20:724

- 16 Nüchel H, Hüttmann A, Klein-Hitpass L, Schroers R, Führer A, Sellmann L, Dührsen U, Dürig J:
LPL expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia.
Leukemia and Lymphoma 2006; 47:1053-61

- 17 Hüttmann A, Klein-Hitpass L, Thomale J, Deenen R, Carpinteiro A, Nüchel H, Ebeling P, Führer A, Edelmann J, Sellmann L, Dührsen U, Dürig J:
Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status.
Leukemia 2006; 20:1774

- 18 Frey UH, Nüchel H, Sellmann L, Siemer D, Küppers R, Dürig J, Dührsen U, Siffert W:
The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia.
Clin. Cancer Research 2006; 12:5686-92

- 19 Riemann K, Becker L, Struwe H, Nüchel H, Dührsen U, Alakus H, Winde G, Neuhauser M, Rübber H, Schmitz KJ, Wohlschläger J, Schmid KW, Siffert W:
No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia.
Pharmacogenet Genomics. 2006; 16:783-788

- 20 Nüchel H, Frey UH, Bau M, Sellmann L, Stanelle J, Dürig J, Jöckel KH, Dührsen U, Siffert W:
Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.
Blood 2007; 109:290-7

- 21 Aydin S, Dührsen U, Nüchel H:
Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Ann Hematol. 2007; 86:271-6

- 22 Sellmann L, Gesk S, Walter C, Ritgen M, Harder L, Martin-Subero JI, Schroers R, Siemer D, Nüchel H, Dyer MJ, Dührsen U, Siebert R, Dürig J, Küppers R:
Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia
Br J Haematol. 2007;138: 217-20

- 23 Rebmann V, Nüchel H, Dührsen U, Grosse-Wilde:

HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications
Semin Cancer Biol. 2007; 17:430-5

- 24 Bachmann HS, Otterbach F, Callies R, Nüchel H, Bau M, Schmid KW, Siffert W, Kimmig R:
The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients
Clin Cancer Res. 2007;13: 5790-7
- 25 Ortmann C, Eisele L, Nüchel H, Klein-Hitpass L, Führer A, Dührsen U, Zeschnigk M:
Correlation of PRAME activation and PRAME hypomethylation in acute myeloid leukemia
Annals of Haematology 2008; 87:809-18
- 26 Röth A, de Beer D, Nüchel H, Sellmann L, Dührsen U, Dürig J, Baerlocher GM:
Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38+ chronic lymphocytic leukaemia
Br J Haematol. 2008; 143:383-6
- 27 Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nüchel H, Lang S, Schmid KW, Siffert W, Bachmann HS:
The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma
Ann Oncol. 2009; 20:1094-9
- 28 Eisele L, Prinz R, Klein-Hitpass L, Nüchel H, Lowinski K, Thomale J, Moeller LC, Dührsen U, Dürig J:
Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia
Eur J Haematol. 2009; 83:320-7
- 29 Wedemeyer C, Kauther MD, Hanenkamp S, Nüchel H, Bau M, Siffert W, Bachmann HS:
BCL2-938C>A and CALCA-1786T>C Polymorphisms in Aseptic Loosened Total Hip Arthroplasty
Eur J Med Res. 2009; 14:250-55
- 30 Fingas CD, Katsounas A, Kahraman A, Siffert W, Jochum C, Gerken G, Nüchel H, Canbay A:
Prognostic assessment of three single-nucleotide polymorphisms (GNB3825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma.
Cancer Investigation 2010; 28:472-8
- 31 Nüchel H, Frey UH, Sellmann L, Collins CH, Dührsen U, Siffert W:
The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia
Br J Haematol. 2009;144:268-70

- 32 Nüchel H, Switala M, Collins CH, Sellmann L, Grosse-Wilde H, Dührsen U, Rebmann V:
High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia
Clin Immunol. 2009; 131:472-80
- 33 Nüchel H, Collins CH, Frey UH, Sellmann L, Dürig J, Siffert W, Dührsen U:
FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia
Eur J Haematol. 2009; 83:541-9
- 34 Zenz T, Benner A, Dührsen U, Dürig J, Döhner H, Siffert W, Stilgenbauer S, Nüchel H:
BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia
Leuk Lymphoma 2009; 11:1-6
- 35 Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R, Nüchel H:
Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.
Int J Bio Markers 2009; 24:223-9
- 36 Nüchel H, Switala M, Sellmann L, Horn PA, Dürig J, Dührsen U, Küppers R, Grosse-Wilde H, Rebmann V:
The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia
Leukemia 2010; 24:1152-9
- 37 Johansson P, Eisele L, Klein-Hitpass L, Sellmann L, Dührsen U, Dürig J, Nüchel H:
Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia
Leukemia Res 2010; 34:892-8
- 38 Bachmann HS, Novotny JR, Sixt S, Liebisch P, Frey UH, Peters J, Dührsen U, Siffert W, Nüchel H:
The G-Allele of the PSMA6 -8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels.
Eur J Haematol. 2010; 85:108-13
- 39 Khandanpour C, Thiede C, Sharif-Askari E, Nüchel H, Lohmann D, Horsthemke B, Siffert W, Neubauer A, Grzeschik KH, Bloomfield CD, Marcucci G, Maharry K, Slovak ML, van der Reijden BA, Jansen JH, Schackert HK, Afshar K, Schnittger S, Peeters JK, Kroschinsky F, Ehninger G, Löwenberg B, Dührsen U, Möröy T:
A variant allele of growth factor independence 1 (GF11) is associated with acute myeloid leukemia
Blood 2010; 115:2462-72
- 40 Meyer C, Ansorge N, Siglienti I, Salmen S, Stroet A, Nüchel H, Dührsen U, Ritter PR,

Schmidt WE, Gold R, Chan A:

Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia.

Nervenarzt 2010; 81:1483-9

- 41 Sellmann L, Scholtysik R, Kreuz M, Cyrull S, Tiacci E, Stanelle J, Carpinteiro A, Nüchel H, Boes T, Gesk S, Siebert R, Klein-Hitpass L, Dührsen U, Dürig J, Küppers R:
Gene dosage effects in chronic lymphocytic leukemia.
Cancer Genet Cytogenet. 2010; 203:149-60
- 42 Sellmann L, de Beer D, Bartels M, Opalka B, Nüchel H, Dührsen U, Dürig J, Seifert M, Siemer D, Küppers R, Baerlocher GM, Röth A:
Telomeres and prognosis in patients with chronic lymphocytic leukaemia
Int J Hematology 2011; 93:74-82
- 43 Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nüchel H, Eisenhardt A, Rübber H, Schmid KW, Siffert W, Eggert A, Schramm A, Schulte JH:
Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.
Int J Cancer 2011; 129 : 2390-9
- 44 Hindy NE, Bachmann HS, Lambertz N, Adamzik M, Nüchel H, Worm K, Zhu Y, Sure U, Siffert W, Sandalcioglu IE:
Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.
J Neurosurg 2011; 114:1631-9
- 45 Westekemper H, Schallenberg M, Tomaszewski A, Nüchel H, Sauerwein W, Meller D, Steuhl K:
Malignant Epibulbar Tumours: New Strategies in Diagnostics and Therapy
Klinisches Monatsblatt für Augenheilkunde 2011; 228 : 780-92
- 46 Wree A, Canbay A, Müller-Beißenhirtz H, Dechêne A, Gerken G, Dührsen U, Lammert F, Nüchel H:
Excessive Bilirubin Elevation in a Patient with Hereditary Spherocytosis and Intrahepatic Cholestasis
Zeitschrift für Gastroenterologie 2011; 49:977-980
- 47 Aydin S, Grabellus F, Eisele L, Möllmann M, Hanoun M, Ebeling P, Moritz T, Carpinteiro A, Nüchel H, Sak A, Göthert JR, Dührsen U, Dürig J:
Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model

Eur J Haematol. 2011; 87:10-9

- 48 Sellmann L, Carpinteiro A, Nüchel H, Scholtysik R, Siemer D, Klein-Hipass L, Kube D, Dürig J, Dührsen U, Stanelle J, Küppers R:
p53 protein expression in chronic lymphocytic leukemia
Leukemia and Lymphoma 2012; 53:1282-8
- 49 Nüchel H, Langer C, Herget-Rosenthal S, Wichert M, Assert R, Döhner H, Dührsen U, Liebisch P:
Prognostic significance of serum cystatin C in multiple myeloma
Int J Hematology 2012; 95:545-50
- 50 Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Friedemann P, Flachenecker P, Fleischer V, Zipp F, Nüchel H, Kieseier BC, Ziegler A, Gold R, Chan A:
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany
Ther Adv Neurol Disord. 2012; 5:75-9
- 51 Nüchel H, Castelli EC, Moreau P, Ochsenfarth C, Horn PA, Rebmann V:
Simple methods for the detection of HLA-G variants in coding and non-coding regions
Methods Mol Biol. 2012;882:123-42
- 52 Nüchel Holger:
Lenalidomid 5 Jahre nach Markteinführung: Studiendaten und klinische Erfahrung belegen den Nutzen der Zweitlinientherapie mit Lenalidomid / Dexamethason für Patienten mit multiplem Myelom
Blickpunkt Medizin, Tumordiagnostik & Therapie 2012; 33. Jahrgang, Heft 8
- 53 Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nüchel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V.:D49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.
J Clin Oncol. 2014;32(9):897-904
- 54 Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nüchel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T:

European Research Initiative on CLL (ERIC) MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Haematologica. 2014;99(8):1285-91

- 55 Sellmann L, Scholtysik R, de Beer D, Eisele L, Klein-Hitpass L, Nüchel H, Dührsen U, Dürig J, Röth A, Baerlocher GM:

Shorter telomeres correlate with an increase in the number of uniparental disomies in patients with chronic lymphocytic leukemia

Leuk Lymphoma. 2016;57:590-5

- 56 Nolte F, Nüchel H, Schmidt B, Geer T, Rubanov O, Hebart H, Jarisch A, Albrecht S, Johr C, Schumann C, Hoffmann WK

Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.

J Cancer Res Clin Oncol (2018) 144: 1531

- 57 Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nüchel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U:

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the „Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas“ (PETAL) trial

Annals of Hematology 2019;98:897-90

- 58 Iron Chelation Therapy in German MDS Patients with Chronic Iron Overload Under Routine Clinical Practice: An Interim Analysis of EXCALIBUR Study

Metz M, Koenigsmann M, Nüchel H, von der Heyde E, Ketzler-Henkel S, Hauch U, Spohn C, Schick A, Johr C, Germing U

Oncology Research and Treatment, 42 (Supp 4), 2019 # P3734), 2019